Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

atrial fibrilliation

- PMLiVE

Pfizer’s Braftovi combination therapy shows positive results for colorectal cancer

Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022

- PMLiVE

Pfizer’s Hympavzi significantly reduces bleeds in haemophilia patients

Over 800,000 people worldwide live with haemophilia

- PMLiVE

Pfizer’s PADCEV gets FDA approval for bladder cancer

Bladder cancer affects more than 614,000 people globally each year

- PMLiVE

Pfizer and Metsera agree on merger after bidding war between Pfizer and Novo Nordisk

The Pfizer bid was chosen by Metsera after a concern was raised about US antitrust laws regarding the Novo Nordisk offer

- PMLiVE

BMS, Macmillan and 11 NHS Trusts publish report on cancer treatment prehabilitation

The report shows how prehabilitation can improve patient experience while alleviating capacity pressures

- PMLiVE

BMS acquires Orbital Therapeutics in $1.5bn deal

The deal includes several next-gen cell therapy candidates for autoimmune diseases

- PMLiVE

Pfizer’s Lorviqua recommended by NICE for lung cancer

Lung cancer is the leading cause of cancer-related deaths worldwide

- PMLiVE

BMS, Takeda and Astex join AI training consortium

The initiative focuses on training AI models to aid in drug discovery and development

- PMLiVE

Pfizer agrees pricing and distribution deal with US government

The agreement enables US patients to access medicines at a discount, in addition to providing Pfizer with relief from US tariffs

Bayer symbol

Bayer’s Kerendia granted FDA approval for new heart failure indication

Approximately 55% of the 6.7 million adults in the US with HF have an LVEF of at least 40%

- PMLiVE

Pfizer/Astellas share positive overall survival results for Xtandi in prostate cancer

Around 55,100 cases of prostate cancer are diagnosed in the UK every year

- PMLiVE

Pfizer shares positive phase 3 results for haemophilia A and B therapy Hympavzi

Around 20% and 3% of haemophilia A and B patients, respectively, develop inhibitors

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links